BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026
Weighted avg shares (diluted) grows in line with its trailing trend
Q3 FY2026 weighted avg shares (diluted) of 193.59M shares rose 0.8% year over year, ahead of the +0.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.8% holds above the trailing-twelve-month pace of +0.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 197.39M USD
- Year-over-year change
- +0.3%
- 4-year CAGR
- +1.9%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 197.39M | +0.3% |
| FY2024 | 2024-12-31 | 196.71M | +2.7% |
| FY2023 | 2023-12-31 | 191.6M | +1.4% |
| FY2022 | 2022-12-31 | 188.96M | +3.3% |
| FY2021 | 2021-12-31 | 182.85M | — |
Weighted Avg Shares (Diluted) vs competitors
How BMRN compares with its peers on the latest reported figures
- BMRN's LTM Sep 2026 weighted avg shares (diluted) of 195.7M shares is the 3rd highest of the 11 companies compared; the peer median is 118.6M shares.
- Its year-over-year change of +0.1% is the 8th highest of 11, against a peer median of +4.5%.
- Over three fiscal years its annual growth of +1.5% compares with a peer median of +5.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 255.83M | -1.3% | -0.1% | |
| LTM Jun 2026 | 214.47M | +18.7% | +20.2% | |
| LTM Sep 2026 | 195.7M | +0.1% | +1.5% | |
| LTM Jun 2026 | 194.58M | +2.6% | +10.2% | |
| LTM Sep 2026 | 164.62M | -0.2% | +4.1% | |
| LTM Jun 2026 | 137.53M | +6.5% | +3.4% | |
| LTM Mar 2026 | 99.68M | +6.6% | +12.1% | |
| LTM Sep 2026 | 92.57M | +2.0% | +11.8% | |
| LTM Jun 2026 | 85.59M | +7.4% | +7.2% | |
| LTM Mar 2026 | 69.93M | -1.6% | -5.4% | |
| LTM Sep 2026 | 65.73M | +7.4% | +2.6% | |
| Peer median (excluding BMRN) | 118.6M | +4.5% | +5.6% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.85B | 2.1B | 2.42B | 2.85B | 3.22B |
| Cost of Revenue | 470.52M | 503.02M | 532.06M | 580.24M | 736.83M |
| Gross Profit | 1.38B | 1.59B | 1.89B | 2.27B | 2.48B |
| Gross Margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% |
| Research & Development | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
| Selling, General & Admin | 759.4M | 823.2M | 892.4M | 1.01B | 1.28B |
| Operating Expenses | 1.46B | 1.43B | 1.7B | 1.79B | 1.95B |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| EBITDA | 47.43M | 265.36M | 306.77M | 650.53M | 572.94M |
| EBITDA Margin | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
| Operating Income | (82.34M) | 160.97M | 185.77M | 484.21M | 533.48M |
| Operating Margin | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% |
| Interest Income | 10.48M | 18.03M | 58.34M | 74.88M | 74.9M |
| Interest Expense | 15.34M | 15.97M | 17.34M | 12.67M | 10.9M |
| Other Income / Expenses | 6.99M | (11.4M) | 2.79M | 57.55M | (51M) |
| Income Before Tax | (75.35M) | 149.58M | 188.56M | 541.76M | 482.48M |
| Pre-Tax Margin | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% |
| Income Tax Expense | (11.27M) | 8.02M | 20.92M | 114.9M | 133.58M |
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Net Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (Basic) | (0.35) | 0.76 | 0.89 | 2.25 | 1.82 |
| EPS (Diluted) | (0.35) | 0.75 | 0.88 | 2.21 | 1.80 |
| Weighted Avg Shares | 182.85M | 185.27M | 187.83M | 190.03M | 191.79M |
| Weighted Avg Shares (Diluted) | 182.85M | 188.96M | 191.6M | 196.71M | 197.39M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.